Photocure (PHO)

Currency in NOK
67.30
-7.40(-9.91%)
Real-time Data·
Unusual trading volume
PHO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
67.0072.80
52 wk Range
48.5079.80
Key Statistics
Prev. Close
74.7
Open
71.4
Day's Range
67-72.8
52 wk Range
48.5-79.8
Volume
238.33K
Average Volume (3m)
90.64K
1-Year Change
37.8229%
Book Value / Share
18.2
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PHO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
82.50
Upside
+22.59%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Photocure News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreement with Richard Wolf GmbH to develop and commercialize a 4K LED high-definition reusable blue light cystoscope based on Richard Wolf’s System blue technology. It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. The company operates in the Nordic countries, Germany, France, Austria, the United Kingdom, the Benelux, Italy, rest of the Europe, Canada, and the United States. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.

Employees
100
Market
Norway

Photocure Earnings Call Summary for Q2/2025

  • Q2 revenue of NOK 135.6M beat forecasts, up 11% YoY; stock surged 12.01% post-earnings
  • Positive EBITDA of NOK 14.8M; 15% revenue growth in North America, 8% in Europe
  • Maintained guidance of 7-11% product revenue growth; advancing FDA reclassification efforts
  • Strong cash position of NOK 239.1M; focus on reinvestment over dividends for future growth
  • Aiming to expand Fortech partnership to 20% of business; emphasizing blue light cystoscopy leadership
Last Updated: 30/07/2025, 15:12
Read Full Transcript

Compare PHO to Peers and Sector

Metrics to compare
PHO
Peers
Sector
Relationship
P/E Ratio
−1,308.4x13.3x−0.5x
PEG Ratio
−25.500.110.00
Price/Book
4.1x2.7x2.6x
Price / LTM Sales
3.7x1.8x3.2x
Upside (Analyst Target)
10.4%15.6%44.7%
Fair Value Upside
Unlock3.8%5.7%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 82.50
(+22.59% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
18/02/2026
EPS / Forecast
-0.30 / 0.26
Revenue / Forecast
136.67M / 138.8M
EPS Revisions
Last 90 days

FAQ

What Is the Photocure (PHO) Share Price Today?

The Photocure stock price today is 67.30 NOK.

What Stock Exchange Does Photocure (PHO) Trade On?

Photocure is listed and trades on the Oslo Stock Exchange.

What Is the Ticker (Stock Symbol) for Photocure?

The stock symbol (also called a 'ticker') for Photocure is "PHO."

What Is the Current Photocure Market Cap?

As of today, Photocure market cap is 1.79B NOK.

What Is Photocure's (PHO) Earnings Per Share (TTM)?

The Photocure EPS is currently -0.06 (Trailing Twelve Months).

When Is the Next Photocure Earnings Date?

Photocure's next earnings report will be released on 07/05/2026.

Is PHO a Buy or Sell From a Technical Analyst Perspective?

Based on today's Photocure moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Photocure Stock Split?

Photocure has split 1 times. (See the PHO stock split history page for full effective split date and price information.)

How Many Employees Does Photocure Have?

Photocure has 100 employees.

What is the current trading status of Photocure (PHO)?

As of 21/04/2026, Photocure (PHO) is trading at a price of 67.30 NOK, with a previous close of 74.70 NOK. The stock has fluctuated within a day range of 67.00 NOK to 72.80 NOK, while its 52-week range spans from 48.50 NOK to 79.80 NOK.

What Is Photocure (PHO) Price Target According to Analysts?

The average 12-month price target for Photocure is 82.50 NOK, with a high estimate of 90 NOK and a low estimate of 75 NOK. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +22.59% Upside potential.

Industry Spotlight

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.